Cited by 625Pancreatic function and diabetesMetabolism and Genetic DisordersDiabetes Management and Research

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index; none of the 92 sources its claims cite is checked for support yet.

Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children

Open access

Abstract

During the first 24-48 hours of life, as normal neonates transition from intrauterine to extrauterine life, their plasma glucose (PG) concentrations are typically lower than later in life.1Cornblath M. Reisner S.H. Blood glucose in the neonate and its clinical significance.N Engl J Med. 1965; 273: 378-381Crossref PubMed Scopus (116) Google Scholar, 2Srinivasan G. Pildes R.S. Cattamanchi G. Voora S. Lilien L.D. Plasma glucose values in normal neonates: a new look.J Pediatr. 1986; 109: 114-117Abstract Full Text PDF PubMed Scopus (225) Google Scholar, 3Stanley C.A. Rozance P.J. Thornton P.S. De Leon D.D. Harris D. Haymond M.W. et al.Re-evaluating “transitional neonatal hypoglycemia”: mechanism and implications for management.J Pediatr. 2015; 166: 1520-1525Abstract Full Text Full Text PDF PubMed Scopus (128) Google Scholar Published guidelines for screening at-risk newborns and managing low PG concentrations in neonates focus on the immediate neonatal period, but do not address the diagnosis and management of disorders causing recurrent and prolonged hypoglycemia.4Canadian Paediatric SocietyScreening guidelines for newborns at risk for low blood glucose.Paediatr Child Health. 2004; 9: 723-740PubMed Google Scholar, 5Adamkin D.H. Postnatal glucose homeostasis in late-preterm and term infants.Pediatrics. 2011; 127: 575-579Crossref PubMed Scopus (424) Google Scholar, 6Wight N. Marinelli K.A. ABM clinical protocol 1: guidelines for glucose monitoring and treatment of hypoglycemia in breastfed neonates.Breastfeed Med. 2006; 1: 178-184Crossref PubMed Scopus (27) Google Scholar Distinguishing between transitional neonatal glucose regulation in normal newborns and hypoglycemia that persists or occurs for the first time beyond the first 3 days of life is important for prompt diagnosis and effective treatment to avoid serious consequences, including seizures and permanent brain injury.Moreover, the evaluation and management of pediatric hypoglycemia differ in several respects from that in adults, for whom guidelines were recently published.7Cryer P.E. Axelrod L. Grossman A.B. Heller S.R. Montori V.M. Seaquist E.R. et al.Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab. 2009; 94: 709-728Crossref PubMed Scopus (704) Google Scholar First, persistent hypoglycemia most often results from a congenital or genetic defect in regulating secretion of insulin, deficiency of cortisol and/or growth hormone, or defects in the metabolism of glucose, glycogen, and fatty acids. Second, it may be difficult to identify and distinguish newborn infants with a persistent hypoglycemia disorder from those with transitional low glucose levels in the initial 48 hours of life, as detailed in the separate document on transitional neonatal hypoglycemia prepared by our committee.3Stanley C.A. Rozance P.J. Thornton P.S. De Leon D.D. Harris D. Haymond M.W. et al.Re-evaluating “transitional neonatal hypoglycemia”: mechanism and implications for management.J Pediatr. 2015; 166: 1520-1525Abstract Full Text Full Text PDF PubMed Scopus (128) Google Scholar Third, the first few months of life are the most vulnerable period for developmental disability, which occurs in ∼25%-50% of children with congenital hyperinsulinism. Early recognition and treatment are crucial for preventing these sequelae.8Menni F. de Lonlay P. Sevin C. Touati G. Peigne C. Barbier V. et al.Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia.Pediatrics. 2001; 107: 476-479Crossref PubMed Scopus (271) Google Scholar, 9Steinkrauss L. Lipman T.H. Hendell C.D. Gerdes M. Thornton P.S. Stanley C.A. Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism.J Pediatr Nurs. 2005; 20: 109-118Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar, 10Meissner T. Wendel U. Burgard P. Schaetzle S. Mayatepek E. Long-term follow-up of 114 patients with congenital hyperinsulinism.Eur J Endocrinol. 2003; 149: 43-51Crossref PubMed Scopus (157) Google ScholarTo address these deficiencies, the Pediatric Endocrine Society convened an expert panel of pediatric endocrinologists and neonatologists to develop guidelines for managing hypoglycemia in neonates, infants, and children, but excluding children with diabetes. The goals of these guidelines are to help physicians recognize persistent hypoglycemia disorders, guide their expeditious diagnosis and effective treatment, and prevent brain damage in at-risk babies.MethodsEvidence Retrieval and RatingThe committee searched for existing evidence synthesis reports, systematic reviews, and meta-analyses. The committee also evaluated guidelines published by the Endocrine Society, American Academy of Pediatrics, Canadian Pediatric Society, and others, and reviewed their bibliographies.4Canadian Paediatric SocietyScreening guidelines for newborns at risk for low blood glucose.Paediatr Child Health. 2004;

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This Pediatric Endocrine Society guideline provides expert recommendations for identifying and managing persistent hypoglycemia in neonates, infants, and children, excluding children with diabetes. It emphasizes distinguishing transitional neonatal hypoglycemia from persistent disorders, confirming low plasma glucose with laboratory assays, and using age- and diagnosis-specific treatment targets.

Key findings

  • For children able to communicate symptoms, evaluate/manage only when Whipple’s triad is documented (GRADE 1++++); for infants/young children unable to communicate reliably, evaluate/manage when laboratory-confirmed plasma glucose is <60 mg/dL (3.3 mmol/L) (GRADE 2+++0).
  • For high-risk neonates suspected of a persistent hypoglycemia disorder, delay diagnostic evaluation until ≥48 hours of age to allow transitional glucose regulation to pass (GRADE 2++00).
  • Treatment targets: maintain plasma glucose >70 mg/dL (3.9 mmol/L) in neonates with suspected congenital hypoglycemia disorder and older infants/children with confirmed disorder (GRADE 1++00); for high-risk neonates without suspected congenital disorder, target >50 mg/dL (>2.8 mmol/L) if <48 hours and >60 mg/dL (>3.3 mmol/L) if >48 hours (GRADE 2+000).
  • During fasting tests, plasma glucose of 50 mg/dL (2.8 mmol/L) is sufficiently low for diagnosis; in suspected hyperinsulinism, a glucagon-induced glycemic rise >30 mg/dL (>1.7 mmol/L) is nearly pathognomonic, and inappropriately low BOHB (<1.5 mmol/L [<15 mg/dL]) and FFA (<1.0–1.5 mmol/L [<28–42 mg/dL]) support the diagnosis.

Methods

  • An expert panel of pediatric endocrinologists and neonatologists convened by the Pediatric Endocrine Society developed guidelines for neonates, infants, and children, excluding children with diabetes.
  • The committee searched for existing evidence synthesis reports, systematic reviews, and meta-analyses; evaluated guidelines from the Endocrine Society, American Academy of Pediatrics, Canadian Pediatric Society, and others; reviewed bibliographies; and identified additional individual studies.
  • Recommendations were graded using the GRADE framework, with strong recommendations stated as “we recommend” (GRADE 1) and weak recommendations as “we suggest” (GRADE 2); a consensus process was used for technical suggestions where evidence was scarce.

Limitations

  • The paper states that evidence in this area is scarce and that the committee used a consensus process for some technical suggestions.
  • The paper states there is an absence of evidence on the short-term or long-term consequences of different treatment targets, so the committee focused on physiology, etiology, mechanism, and risk–benefit balance.
  • The text notes controversy over whether the newborn brain has greater or lesser susceptibility to hypoglycemic injury; evident from the text, several recommendations rely on expert consensus and extrapolation from adult/older-child physiology rather than direct pediatric outcome trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.jpeds.2015.03.057

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 92 cited sources checked · 0 supported · 0 flagged

Show all 37 claims

  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 6
20 of 20
  • The paper relies on this without support.

    Persistent hypoglycemia most often results from a congenital or genetic defect in regulating insulin secretion, deficiency of cortisol and/or growth hormone, or defects in the metabolism of glucose, glycogen, and fatty acids.

    “First, persistent hypoglycemia most often results from a congenital or genetic defect in regulating secretion of insulin, deficiency of cortisol and/or growth hormone, or defects in the metabolism of glucose, glycogen, and fatty acids.”
  • The paper relies on this without support.

    Hypoglycemia disorders in older infants and children are uncommon.

    “Hypoglycemia disorders in older infants and children are uncommon.”
  • The paper relies on this without support.

    Adrenal insufficiency, congenital or acquired, may manifest with hypoglycemia.

    “Adrenal insufficiency, congenital or acquired, may manifest with hypoglycemia.”
  • The paper relies on this without support.

    High plasma insulin level but low C-peptide level during hypoglycemia suggest exogenous insulin administration.

    “High plasma insulin level but low C-peptide level during hypoglycemia suggest exogenous insulin administration.”
  • The paper relies on this without support.

    The drugs most commonly associated with hypoglycemia include insulin, sulphonylureas, alcohol, beta-blockers, and salicylates.

    “The drugs most commonly associated with hypoglycemia include insulin, sulphonylureas, alcohol, beta-blockers, and salicylates.”
  • The paper relies on this without support.

    Not all commercially available insulin assays measure the insulin analogues; thus the finding of low insulin and C-peptide levels at time of hypoglycemia might not rule out surreptitious insulin administration.

    “Not all commercially available insulin assays measure the insulin analogues; thus, the finding of low insulin and C-peptide levels at time of hypoglycemia might not rule out surreptitious insulin administration.”
  • The paper relies on this without support.

    A plasma glucose concentration of 50 mg/dL is sufficiently low to elicit the metabolic and neuroendocrine responses required for diagnosis.

    “A PG concentration of 50 mg/dL (2.8 mmol/L) is sufficiently low to elicit the metabolic and neuroendocrine responses required for diagnosis.”
  • The paper relies on this without support.

    With few exceptions, blood tests performed while glucose concentrations are normal are not informative.

    “With few exceptions, blood tests performed while glucose concentrations are normal are not informative.”
  • The paper relies on this without support.

    Laboratory reference ranges for some tests (eg, insulin, BOHB) may be inappropriate for interpreting values obtained during childhood hypoglycemia.

    “Laboratory reference ranges for some of these tests (eg, insulin, BOHB) may be inappropriate for interpreting values obtained during childhood hypoglycemia.”
  • The paper relies on this without support.

    In cases of hyperinsulinism, glucagon can be expected to raise plasma glucose concentration to normal or above within 10–15 minutes and to maintain that concentration for at least 1 hour.

    “In cases of hyperinsulinism, glucagon can be expected to raise PG concentration to normal or above within 10–15 minutes and to maintain that concentration for at least 1 hour.”
  • The paper relies on this without support.

    Doses of glucagon 0.5–1.0 mg (independent of weight), given IV, intramuscularly, or subcutaneously, are usually effective; lower doses (0.03 mg/kg) may carry less risk of transient nausea and vomiting, but may be ineffective unless given IV.

    “Doses of 0.5–1.0 mg (independent of weight), given IV, intramuscularly, or subcutaneously, are usually effective; lower doses (0.03 mg/kg) may carry less risk of transient nausea and vomiting, but may be ineffective unless given IV.”
  • The paper relies on this without support.

    For disorders such as defects in glycogen metabolism and gluconeogenesis, maintenance of plasma glucose concentration in the normal range prevents metabolic acidosis and growth failure, and possibly the development of long-term complications.

    “For disorders such as defects in glycogen metabolism and gluconeogenesis, maintenance of PG concentration in the normal range prevents metabolic acidosis and growth failure, and possibly the development of long-term complications.”
  • The paper relies on this without support.

    There is no evidence that the concentration at which plasma glucose becomes limiting for brain function is different in neonates than in older children and adults.

    “There is no evidence that the concentration at which PG becomes limiting for brain function is different in neonates than in older children and adults.”
13 of 13

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 601–625 of 625

Metadata

Authors
Thornton, P. S., Stanley, C. A., De Leon, D. D., Harris, D., Haymond, M. W., Hussain, K., Levitsky, L. L., Murad, M. H., Rozance, P. J., Simmons, R. A., Sperling, M. A., Weinstein, D. A., White, N. H., & Wolfsdorf, J. I.
Affiliations
  • Cook Children's Medical Center (US)
  • Children's Hospital of Philadelphia (US)
  • Waikato District Health Board (NZ)
  • Texas Children's Hospital (US)
  • Great Ormond Street Hospital (GB)
  • Massachusetts General Hospital (US)
  • Mayo Clinic (US)
  • University of Colorado Anschutz (US)
  • Children's Hospital of Pittsburgh (US)
  • University of Florida Health (US)
  • Washington University in St. Louis (US)
  • Boston Children's Hospital (US)
Corresponding author
Thornton, Paul S.
Venue
The Journal of Pediatrics
Publisher
Elsevier BV
Published
2015-08
Volume
167
Issue
2
Pages
238-245
ISSN
0022-3476 (ISSN-L)
OpenAlex
W1585861318
Cited by
625
References
44
Citations by year
2026: 54 · 2025: 36 · 2024: 71 · 2023: 62 · 2022: 73 · 2021: 80 · 2020: 72 · 2019: 54 · 2018: 46 · 2017: 33 · 2016: 31 · 2015: 11
FWCI
40.41
Type
journal article
Language
en
Open access
Locations
  • The Journal of Pediatrics (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK088139, R01DK055704)
  • National Institute of Environmental Health Sciences (P30ES013508)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
persistent hypoglycemia, neonatal hypoglycemia, infants, children, plasma glucose, hypoglycemia management, hypoglycemia etiology, hypoglycemia screening, hypoglycemia treatment, hypoglycemia diagnosis, hypoglycemia
MeSH terms
Blood Glucose, Child, Child, Preschool, Endocrinology, Humans, Hypoglycemia, Infant, Infant, Newborn, Pediatrics, Societies, Medical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review